Chronic Lymphocytic Leukemia (CLL) Treatment Options & Guide

Treatment for Chronic Lymphocytic Leukemia

Treatment for chronic lymphocytic leukemia (CLL) is highly individualized, depending on the stage of the disease, the presence of symptoms, genetic characteristics of the leukemia cells, a person’s age and overall health. Often, a combination of treatments is employed.

Watchful Waiting: A Common First Step

For many individuals newly diagnosed with CLL, particularly if the disease is caught early, progressing slowly, and not causing any noticeable symptoms, a “watch and wait” approach is often recommended. This involves careful monitoring of the condition through regular blood tests and physical examinations, typically every three to six months, without initiating active treatment.

Research indicates that immediate treatment in these early stages doesn’t necessarily improve survival outcomes. Because treatment itself can carry side effects, and some individuals may never require intervention, observation is a standard practice. It’s important to understand that “watch and wait” doesn’t mean ignoring the condition; it means proactively monitoring it for any signs of progression.

Targeted Therapies: A First-Line Option

Targeted therapies represent a significant advancement in CLL treatment. These medications work by specifically blocking proteins on cancerous cells, interfering with their growth and survival. Due to their often milder side effect profiles compared to traditional chemotherapy, targeted therapies are frequently considered as a first-line treatment option.

Several targeted therapies are currently available, including:

• acalabrutinib (Calquence)
• ibrutinib (Imbruvica)
• idelalisib (Zydelig)
• pirtobrutinib (Jaypirca)
• venetoclax (Venclexta)
• zanubrutinib (Brukinsa)

Chemotherapy: A Continued Role

Chemotherapy involves the use of powerful medications, administered either orally or intravenously, to kill rapidly dividing cancer cells. While targeted therapies are increasingly favored, chemotherapy remains a viable option, particularly for individuals who are unable to tolerate targeted medications or who have a more aggressive form of CLL.

Immunotherapy: Harnessing the Body’s Defenses

Immunotherapy leverages the patient’s own immune system to fight cancer. There are several approaches to immunotherapy used in CLL.

Chimeric antigen receptor (CAR) T-cell therapy is a complex process where immune cells are removed from the patient’s blood, genetically engineered to enhance their ability to recognize and destroy leukemia cells, and then infused back into the body. This treatment is typically reserved for cases where targeted therapy has not been successful and can be associated with significant side effects.

Another form of immunotherapy utilizes monoclonal antibodies – laboratory-created proteins designed to bind to specific proteins on cancer cells. This binding can attract the patient’s immune cells to the cancer, facilitating their destruction. Commonly used monoclonal antibodies in CLL treatment include rituximab (Rituxan) and obinutuzumab (Gazyva).

Stem Cell Transplant: An Uncommon Approach

Stem cell transplantation is a less common treatment modality for CLL. It involves using high doses of chemotherapy or radiation to destroy cancerous cells in the bone marrow, followed by the infusion of healthy stem cells – either from the patient themselves (autologous transplant) or from a donor (allogeneic transplant) – to rebuild the blood-forming system.

Radiation Therapy: Targeted Relief

Radiation therapy, which uses high-energy rays to kill cancer cells, is not typically a primary treatment for CLL. However, it may be used to alleviate pain caused by enlarged lymph nodes or to prepare the patient for a stem cell transplant.

Surgery and Leukapheresis: Specialized Interventions

Surgery is generally not curative for CLL, as the disease often spreads throughout the body. However, if CLL causes significant enlargement of the spleen, surgical removal (splenectomy) may be considered to reduce strain on other organs and improve red blood cell counts.

In rare instances, a very high number of CLL cells in the blood can lead to circulation problems. In such cases, a procedure called leukapheresis may be employed. Leukapheresis involves removing blood from the body, filtering out the leukemia cells, and returning the remaining blood components to the patient. This is typically a temporary measure to allow other treatments to become more effective.

The landscape of CLL treatment is continually evolving, with ongoing research leading to new and improved therapies. The best course of action for any individual with CLL should be determined in close consultation with a qualified hematologist-oncologist, taking into account the specifics of their case and the latest medical advancements.